The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ... including benefits in both progression-free and overall survival in frontline treatment, and we continue to observe strong ...

No new safety findings have been observed with continued blarcamesine treatment over three (3) years with good ... Investigator for the blarcamesine Phase IIb/III ANAVEX ® 2-73-AD-004 study.

"The Phase 2 OVATION ... peritoneal cancer. Treatment in the neoadjuvant period is designed to shrink the tumors as much as possible for optimal surgical removal after three cycles of chemotherapy.

1-3 The Phase 2 study is part of a seamless Phase 2 / Phase 3 program that includes three studies: a single Phase 2 study and two Phase 3 studies which have almost identical design. The Phase 2 ...

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...

The trial had an adaptive design in which the ... No patient discontinued study treatment because of an adverse event. In this study, the presence of at least three active peripheral joints ...

A dose-reduction strategy for a commonly used first-line combination in pancreatic cancer resulted in similar survival outcomes but improved tolerability, a randomized phase II study showed.

Aura Biosciences announced that it has received an agreement from the FDA under a special protocol assessment for the design of a phase 3 trial ... for bel-sar for the treatment of early-stage ...